A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection.
Administration, Intranasal
Animals
Antigen Presentation
Cells, Cultured
Cholera Toxin
/ immunology
Humans
Immunogenicity, Vaccine
Immunoglobulin A
/ metabolism
Influenza A virus
/ physiology
Influenza Vaccines
/ immunology
Influenza, Human
/ immunology
Liposomes
/ immunology
Lung
/ immunology
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Nanoparticles
/ metabolism
Orthomyxoviridae Infections
/ immunology
Peptides, Cyclic
Recombinant Fusion Proteins
/ immunology
Th1 Cells
/ immunology
Th17 Cells
/ immunology
Vaccination
Journal
Mucosal immunology
ISSN: 1935-3456
Titre abrégé: Mucosal Immunol
Pays: United States
ID NLM: 101299742
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
06
11
2019
accepted:
24
07
2020
revised:
20
07
2020
pubmed:
19
8
2020
medline:
30
11
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
This is a proof-of-principle study demonstrating that the combination of a cholera toxin derived adjuvant, CTA1-DD, and lipid nanoparticles (LNP) can significantly improve the immunogenicity and protective capacity of an intranasal vaccine. We explored the self-adjuvanted universal influenza vaccine candidate, CTA1-3M2e-DD (FPM2e), linked to LNPs. We found that the combined vector greatly enhanced survival against a highly virulent PR8 strain of influenza virus as compared to when mice were immunized with FPM2e alone. The combined vaccine vector enhanced early endosomal processing and peptide presentation in dendritic cells and upregulated co-stimulation. The augmenting effect was CTA1-enzyme dependent. Whereas systemic anti-M2e antibody and CD4
Identifiants
pubmed: 32807838
doi: 10.1038/s41385-020-0334-2
pii: S1933-0219(22)00151-9
doi:
Substances chimiques
CTA1-DD protein, recombinant
0
Immunoglobulin A
0
Influenza Vaccines
0
Lipid Nanoparticles
0
Liposomes
0
Peptides, Cyclic
0
Recombinant Fusion Proteins
0
dendroamide A
0
Cholera Toxin
9012-63-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
523-536Références
Lycke, N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12, 592–605 (2012).
pubmed: 22828912
Bernasconi, V., Norling, K., Bally, M., Hook, F. & Lycke, N. Y. Mucosal vaccine development based on liposome technology. J. Immunol. Res. 2016, 5482087 (2016).
pubmed: 28127567
pmcid: 5227169
Corthesy, B. & Bioley, G. Lipid-based particles: versatile delivery systems for mucosal vaccination against infection. Front. Immunol. 9, 431 (2018).
pubmed: 29563912
pmcid: 5845866
Pati, R., Shevtsov, M. & Sonawane, A. Nanoparticle vaccines against infectious diseases. Front. Immunol. 9, 2224 (2018).
pubmed: 30337923
pmcid: 6180194
Kaba, S. A. et al. Self-assembling protein nanoparticles with built-in flagellin domains increases protective efficacy of a Plasmodium falciparum based vaccine. Vaccine 36, 906–914 (2018).
pubmed: 29269157
Boyaka, P. N. Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. J. Immunol. 199, 9–16 (2017).
pubmed: 28630108
pmcid: 5719502
Savelkoul, H. F., Ferro, V. A., Strioga, M. M. & Schijns, V. E. Choice and design of adjuvants for parenteral and mucosal vaccines. Vaccines 3, 148–171 (2015).
pubmed: 26344951
pmcid: 4494243
Yusuf, H. & Kett, V. Current prospects and future challenges for nasal vaccine delivery. Hum. Vaccines Immunother. 13, 34–45 (2017).
Kim, S. H. & Jang, Y. S. The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants. Clin. Exp. Vaccine Res. 6, 15–21 (2017).
pubmed: 28168169
pmcid: 5292352
Lambkin, R. et al. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine. Vaccine 22, 4390–4396 (2004).
pubmed: 15474733
Bozzuto, G. & Molinari, A. Liposomes as nanomedical devices. Int. J. Nanomed. 10, 975–999 (2015).
Schwendener, R. A. Liposomes as vaccine delivery systems: a review of the recent advances. Ther. Adv. Vaccines 2, 159–182 (2014).
pubmed: 25364509
pmcid: 4212474
Agren, L. C., Ekman, L., Lowenadler, B., Nedrud, J. G. & Lycke, N. Y. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162, 2432–2440 (1999).
pubmed: 9973526
Eriksson, A. M., Schon, K. M. & Lycke, N. Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol. 173, 3310–3319 (2004).
pubmed: 15322194
Lycke, N. & Lebrero-Fernandez, C. ADP-ribosylating enterotoxins as vaccine adjuvants. Curr. Opin. Pharmacol. 41, 42–51 (2018).
pubmed: 29702466
Bernasconi, V. et al. Porous nanoparticles with self-adjuvanting M2e-fusion protein and recombinant hemagglutinin provide strong and broadly protective immunity against influenza virus infections. Front. Immunol. 9, 2060 (2018).
pubmed: 30271406
pmcid: 6146233
Agren, L., Lowenadler, B. & Lycke, N. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol. Cell Biol. 76, 280–287 (1998).
pubmed: 9682972
Eliasson D. G., et al. M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection. Mucosal Immunol. 11, 273–289 (2017).
pubmed: 28295019
Kolpe, A., Schepens, B., Fiers, W. & Saelens, X. M2-based influenza vaccines: recent advances and clinical potential. Expert Rev. Vaccines 16, 123–136 (2017).
pubmed: 27653543
Deng, L., Cho, K. J., Fiers, W. & Saelens, X. M2e-based universal influenza A vaccines. Vaccines 3, 105–136 (2015).
pubmed: 26344949
pmcid: 4494237
Eliasson, D. G. et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 26, 1243–1252 (2008).
pubmed: 18243429
Kappler, J., White, J., Wegmann, D., Mustain, E. & Marrack, P. Antigen presentation by Ia+ B cell hybridomas to H-2-restricted T cell hybridomas. Proc. Natl Acad. Sci. USA 79, 3604–3607 (1982).
pubmed: 6980413
Murphy, D. B. et al. A novel MHC class II epitope expressed in thymic medulla but not cortex. Nature 338, 765–768 (1989).
pubmed: 2469959
Avalos, A. M. & Ploegh, H. L. Early BCR events and antigen capture, processing, and loading on MHC Class II on B Cells. Front. Immunol. 5, 92 (2014).
pubmed: 24653721
pmcid: 3948085
Ashhurst, A. S. et al. CXCR6-deficiency improves the control of pulmonary mycobacterium tuberculosis and influenza infection independent of T-Lymphocyte recruitment to the lungs. Front. Immunol. 10, 339 (2019).
pubmed: 30899256
pmcid: 6416161
Schild, G. C. et al. Antigenic variation in current human type A influenza viruses: antigenic characteristics of the variants and their geographic distribution. Bull. World Health Organ. 48, 269–278 (1973).
pubmed: 4200741
pmcid: 2481068
Wein, A. N. et al. CXCR6 regulates localization of tissue-resident memory CD8 T cells to the airways. J. Exp. Med. 216, 2748–2762 (2019).
pubmed: 31558615
pmcid: 6888981
Eliasson, D. G. et al. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. Vaccine 29, 3951–3961 (2011).
pubmed: 21481325
Norling, K., et al. Gel Phase 1,2-Distearoyl-sn-glycero-3-phosphocholine-based liposomes are superior to fluid phase liposomes at augmenting both antigen presentation on major histocompatibility complex Class II and costimulatory molecule display by dendritic cells in vitro. ACS Infect. Dis. 5, 1867–1878 (2019).
pubmed: 31498993
Nance, E. et al. Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration. ACS Nano 8, 10655–10664 (2014).
pubmed: 25259648
pmcid: 4212792
Oberoi, H. S., Yorgensen, Y. M., Morasse, A., Evans, J. T. & Burkhart, D. J. PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccination. J. Control Release 223, 64–74 (2016).
pubmed: 26551346
Suk, J. S., Xu, Q., Kim, N., Hanes, J. & Ensign, L. M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99(Pt A), 28–51 (2016).
pubmed: 26456916
Ji, Z., Xie, Z., Zhang, Z., Gong, T. & Sun, X. Engineering intravaginal vaccines to overcome mucosal and epithelial barriers. Biomaterials 128, 8–18 (2017).
pubmed: 28285195
Zhan, X., Tran, K. K. & Shen, H. Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration. Mol. Pharm. 9, 3442–3451 (2012).
pubmed: 23098233
pmcid: 3849130
Xu, Q. et al. Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in Mucus ex vivo and distribution in vivo. ACS Nano 9, 9217–9227 (2015).
pubmed: 26301576
pmcid: 4890729
Watson, D. S., Endsley, A. N. & Huang, L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 30, 2256–2272 (2012).
pubmed: 22306376
pmcid: 3296885
Rincon-Restrepo, M. et al. Vaccine nanocarriers: coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses. Biomaterials 132, 48–58 (2017).
pubmed: 28407494
Schlitzer, A., Zhang, W., Song, M., Ma, X. Recent advances in understanding dendritic cell development, classification, and phenotype. F1000Res. 7, (2018).
Flores-Langarica, A. et al. Intestinal CD103(+)CD11b(+) cDC2 conventional dendritic cells are required for primary CD4(+) T and B cell responses to soluble flagellin. Front. Immunol. 9, 2409 (2018).
pubmed: 30386346
pmcid: 6199373
Helft, J. et al. Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. J. Clin. Investig. 122, 4037–4047 (2012).
pubmed: 23041628
Radford, K. J. & Caminschi, I. New generation of dendritic cell vaccines. Hum. Vaccine Immunother. 9, 259–264 (2013).
Lee, H. et al. Phenotype and function of nasal dendritic cells. Mucosal Immunol. 8, 1083–1098 (2015).
pubmed: 25669151
pmcid: 4532662
Neirynck, S. et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5, 1157–1163 (1999).
pubmed: 10502819
De Filette, M. et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337, 149–161 (2005).
pubmed: 15914228
Leung, H. C. et al. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus. Emerg. Microbes Infect. 4, e22 (2015).
pubmed: 26038770
pmcid: 4417706
Chwalek, M., Lalun, N., Bobichon, H., Ple, K. & Voutquenne-Nazabadioko, L. Structure-activity relationships of some hederagenin diglycosides: haemolysis, cytotoxicity and apoptosis induction. Biochim. Biophys. Acta 1760, 1418–1427 (2006).
pubmed: 16875785
Spangler, B. D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56, 622–647 (1992).
pubmed: 1480112
pmcid: 372891